June 2014 Newsletter

June 18, 2014:

Anti-VEGF Undertreatment Stuns ARVO Audience

Injections for wet AMD are administered at a far less frequent rate than recommended in much of the world, according to data presented at this year’s conference.

June 18, 2014:

ARVO Meeting Returns to Florida

This year’s conference was held May 4 to 8 in Orlando, FL.

June 18, 2014:

ARVO: Highlights of Pipeline Pharma, Biotech, and Delivery Technologies

Presentations on potential ocular anti-angiogenic treatments under investigation ranged from Boehringer-Ingelheim’s cancer therapy Vargatef to Kowa’s topical Rho-kinase inhibitor, which is currently in late-stage development for glaucoma.

June 18, 2014:

ARVO: NEI Reports on Advances in Audacious Goals Initiative

Paul Sieving, MD, PhD, Director of the NEI, updated the work of the project during the past year.

June 18, 2014:

Brutal Weather Slows Q1-2014 Retinal Procedures

Procedure volumes were significantly lower than anticipated with a decline in vitrectomy procedures and a lower-than-expected number of IVT injections.

June 18, 2014:

FDA’s Ophthalmic Devices Panel Provides Mixed Recommendation for AcuFocus KAMRA Inlay

Patient safety was a concern at June 6 meeting.

June 18, 2014:

New AMA President Urges Physicians to Embrace Digital Age

Robert M. Wah, MD, is a nationally recognized expert in health information technology, and he used his inauguration speech on June 10 to encourage physicians to lead the digitizing of health care rather than be led.

June 18, 2014:

Q1-2014 Surveys Indicate Ophthalmologists’ Plans to Adopt New Technology

First-quarter surveys indicate doctors’ interest in adopting new technology.

June 18, 2014:

Demand for Ultrasonic Phaco, Femtosecond Machines will Fuel Solid Growth in Cataract Equipment Market

Revenues are expected to total more than $2.2 billion by 2019.

June 18, 2014:

Italy to Pay for Off-label Use of Avastin in Wet AMD

The move is the latest in series of blows to Roche and Novartis related to the pricing of the two drugs.

June 18, 2014:

Value of Early-Stage Research at Center of Allergan-Valeant Battle

In Valeant’s unsolicited takeover bid of Allergan, Pearson said he planned to cut Allergan’s R&D spending from $1 billion to $300 million, a declaration that sent shivers through the ophthalmic community.

June 18, 2014:

Novartis Raises Bar with Licensing Deal for Fovista

Agreement could be worth more than $1 billion for Ophthotech.

June 18, 2014:

Burwell Takes Over as US Health Secretary

She will oversee the Affordable Care Act, Healthcare.gov, Medicare and Medicaid, the National Institutes of Health, and the FDA.

June 18, 2014:

ASCRS Attendance Update

June 18, 2014:

June 2014 News Briefs

Social media